The 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol retains focus on recommendations for statin treatment in the original four statin-eligible groups [those with atherosclerotic cardiovascular disease (ASCVD), diabetes, low-density lipoprotein cholesterol (LDL-C) ≥ 190 mg/ dL, and higher risk primary prevention] without the use of treatment initiation or target LDL-C levels from the earlier 2013 American College of Cardiology/American Heart Association (ACC/AHA) guideline, but has several new features. First, patients with primary prevention are divided into those who are at low (< 5%), borderline (5% to < 7.5%), intermediate (7.5% to < 20%), and high (≥ 20%) risk based on the ASCVD risk estimator. Moreover, the new guideline goes further to consider a wider range of factors [now called "risk enhancers"-premature family history of ASCVD, persistently high LDL-C, chronic kidney disease (CKD), metabolic syndrome, conditions specific to women, inflammatory diseases, and high-risk ethnicities] that can be used to better inform the treatment decision. Moreover, more detailed recommendations on how the results of coronary calcium scanning can be used to inform the treatment decision are provided, including how it may be used to "de-risk" certain patients for delaying or avoiding the use of statin therapy. There are also specific sections for cholesterol management in other patient subgroups including women, children, certain ethnic groups, those with CKD, chronic inflammatory disorders and HIV, as well as discussion on the management of hypertriglyceridemia. Importantly, for persons with known ASCVD, a distinction is made for those who are at "very high risk" based on having had two major ASCVD events or one major event and two or more other high risk conditions, such as diabetes or other major risk factors, or bypass surgery or percutaneous intervention. Finally, the concept of a threshold LDL-C for initiating a non-statin therapy (after considering highest tolerated statin dosage) is provided, with ezetimibe recommended as the key non-statin to be added if the LDL-C still remains ≥ 70 mg/dL for all ASCVD patients, and in those who are at "very high risk", further consideration for using a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. While the new guideline does have greater detail (and arguably, complexity), the refinements provide a strategy for guiding the clinician to target both statin and non-statin therapy to those most likely to derive benefit.
Key Points
The 2018 Guideline on the Management of Blood Cholesterol provides greater risk stratification for primary prevention, considering the use of a wide range of risk enhancers and detailed recommendations on how results from coronary calcium scoring can be used to better inform the treatment decision.
Specific guidelines are provided for cholesterol management in women, children, older persons, those with inflammatory conditions or HIV, as well as hypertriglyceridemia.
Persons with known atherosclerotic cardiovascular disease (ASCVD) are classified according to whether they are at "very high risk" based on having multiple ASCVD events or a single event with other high-risk conditions, with threshold low-density lipoprotein cholesterol levels noted for the consideration of non-statin therapy.
Introduction
The most recent, 2018, AHA/ACC/AACVPR/AAPA/ABC/ ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol [1] is a substantial collaborative effort among key societies, including authorship from the American Society for Preventive Cardiology (ASPC). While it still retains focus on recommendations for statin treatment in the original four statin-eligible groups from the earlier 2013 American College of Cardiology/ American Heart Association (ACC/AHA) guideline [2] , the new guideline goes further to consider a wider range of factors (now called "risk enhancers") that can be used to better inform the treatment decision, and addresses implications of treatment for other patient subgroups including women, children, certain ethnic groups, those with chronic kidney disease (CKD), chronic inflammatory disorders and HIV, as well as discussion on the management of hypertriglyceridemia. Given that its foundations [e.g., focus on statin therapy recommendations and absence of specific initiation or target levels of low-density lipoprotein cholesterol (LDL-C)] are not substantially different from the 2013 release, it has attracted far less attention and controversy compared to its predecessor.
At the recent American College of Cardiology Scientific Sessions in March 2019, the revised Primary Prevention of Cardiovascular Disease Guidelines [3] were also presented. These were the first such release focusing on primary prevention in more than a decade and were intended to be a compendium of the recent cholesterol and blood pressure guidelines with an update on lifestyle management, and this time also included guidelines for smoking cessation and updated aspirin guidelines to promote disease prevention as a cornerstone of cardiovascular medicine. They included the primary prevention part of the 2018 cholesterol guidelines release. Central to the Primary Prevention of Cardiovascular Disease Guidelines and relevant to cholesterol management is the strong recommendation for patient-centered approaches for comprehensive atherosclerotic cardiovascular disease (ASCVD) prevention, including a team-based approach for control of risk factors for ASCVD (class I recommendation), shared decision making to guide discussions about the best strategies to reduce ASCVD risk (class I recommendation), and use of social determinants of health to inform optimal implementation of treatment recommendations for prevention of ASCVD (class I recommendation).
There are some key similarities and differences between the 2013 and 2018 guidelines. Importantly, the 2018 guidelines have kept the original four key statin eligible groups: those with (1) documented ASCVD, (2) LDL-C ≥ 190 mg/ dL, (3) diabetes, and (4) increased ASCVD risk requiring primary prevention. Within these groups, however, there are further refinements (and arguably, greater complexity) as to the specific recommended therapy needing explanation. Moreover, the clinician/patient discussion, which was a hallmark of the 2013 guidelines, especially with the use of the risk calculator, is even more important with the introduction of additional "risk enhancers" as well as a greater role for use of results from coronary calcium screening, not only for informing the decision to treat, but also, for the first time, identifying patients for whom treatment can perhaps be withheld or delayed. Finally, for those with known ASCVD, criteria are now provided for categorization into those at "very high risk" and "not at very high risk" with treatment algorithms and LDL-C thresholds provided for initiation non-statin therapy for each group.
Lifestyle Management
This remains the cornerstone for prevention of cardiovascular disease, and crucially, a healthy lifestyle is the primary overarching recommendation for all statin eligible patient groups in the cholesterol management guideline. As is the case with the 2013 Lifestyle Management Guideline [4] , the recent 2019 Prevention Guidelines also recommend a dietary pattern comprising an increased intake of vegetables, fruits, whole grains, legumes, healthy protein sources, and non-tropical vegetable oils (class I recommendation), while limiting intake of sweets, sugar-sweetened beverages, and red meats (class IIa recommendation). Physical activity recommendations state 150 min of moderate intensity or 75 min of vigorous intensity physical activity per week (or equivalent combination) to reduce ASCVD risk (class I recommendation).
Primary Prevention
As in the 2013 guideline, the 2018 cholesterol management guideline divides primary prevention groups into those with LDL-C ≥ 190 mg/dL, persons with diabetes (see Sect. 4), and individuals without these conditions. A more detailed algorithm than what was released in 2013, however, is presented ( Fig. 1 ), now with recommendations to consider a statin in those < 20 years of age with a diagnosis of familial hypercholesterolemia, or those 20-39 years of age with a premature family history of ASCVD or LDL-C ≥ 160 mg/dL (class IIa recommendation). In those with severe hypercholesterolemia (LDL-C ≥ 190 mg/dL), high-intensity statin is still the key recommendation, without the need for any risk calculation (class I recommendation). Further, in those achieving a less than 50% reduction in LDL-C on maximally tolerated statin and/or with residual LDL-C ≥ 100 mg/dL, adding ezetimibe is reasonable (class IIa recommendation). And for those with heterozygous familial hypercholesterolemia, use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors can be considered if the LDL-C remains ≥ 100 mg/dL after use of statin and ezetimibe (class IIb recommendation).
Atherosclerotic Cardiovascular Disease Risk Categorization and Risk Enhancers
General primary prevention without diabetes or severe hypercholesterolemia starts with 10-year ASCVD risk estimation using the Pooled Cohort Risk Estimator (which is valid for those aged 40-79 years of age) (class I recommendation), but now subdivides risk categories as follows: low (< 5%), borderline (5% to < 7.5%), moderate (7% to > 20%), and high (≥ 20%) risk of a hard ASCVD event, including myocardial infarction (MI) and stroke. Unlike the 2013 guidelines, in which one was statin eligible if the 10-year ASCVD risk was ≥ 7.5%, the updated guidelines more clearly note the appropriateness of lifestyle recommendations only for persons with a 10-year ASCVD risk < 5%, and statin therapy to reduce LDL-C at least 50% plus lifestyle therapy for those with a 10-year risk ≥ 20%. For those with a 10-year risk of ASCVD between 5% and 20%, a larger number of "risk enhancers" is introduced ( Fig. 1 ), which should be considered in the clinician/ patient discussion concerning the pertinence of statin therapy (class IIa recommendation). This is an update from the four factors introduced in 2013 (premature family history of ASCVD, coronary calcium score ≥ 300 or ≥ the 75th percentile, high-sensitivity C-reactive protein > 2 mg/L, or an ankle-brachial index (ABI) score < 0.9), which were proposed then to inform the treatment decision. The inclusion of conditions specific to women (e.g., premature menopause, pre-eclampsia), inflammatory diseases, CKD, and certain high-risk ethnicities (e.g., South Asians) to inform the treatment decision is particularly welcome. However, it is not clear whether any single condition in the case of someone in the 5% to < 20% risk category automatically makes the person statin eligible, although arguably a severe elevation in any one risk factor would stratify one's risk upward to justify statin therapy. As such, this judgement is up to the clinician, who may consider both number and severity of any risk enhancers present when discussing with the patient the risks and benefits of starting or intensifying statin therapy.
Role of Coronary Artery Calcium Screening
Perhaps the most noticeable addition to the 2018 guidelines for the primary prevention patient is the role of coronary calcium scoring in risk assessment and treatment decisions.
In the new guidelines, rather than being one of four factors used to inform treatment decisions as in previous guidelines, results from coronary calcium scoring are recommended if the treatment decision is still uncertain after considering the risk-enhancing factors described above, and only for those in the borderline (5% to < 7.5%) and intermediate (7.5% to < 20%) 10-year risk categories (class IIa recommendation), where the results of coronary calcium can be used to withhold, postpone, or initiate statin therapy, based on published evidence of its utility in providing further risk stratification over the Pooled Cohort Risk scores [5] . This is an upgraded recommendation from 2013 where coronary artery calcium (CAC) scoring was given a class IIb recommendation. In the case of the new guidelines, for the first time, a zero calcium score is identified as a rationale for withholding or delaying statin therapy (unless there is a family history of premature coronary heart disease, diabetes, or cigarette smoking), a score of 1-99 "favors" statin therapy, and a score of ≥ 100 or ≥ 75th percentile for age and sex is an impetus for statin therapy (the previous 2013 guideline did not recommend coronary calcium to upgrade risk unless the score was ≥ 300 or ≥ the 75th percentile; nor was there any recommendation to "de-risk" the patient if the score was 0). The "derisking" of those with a 0 calcium score is a particularly bold move, supported mainly by observational data from the MESA study, noting those with a 0 score had an ASCVD risk below the 7.5% threshold where net clinical benefit was demonstrated in the 2013 guidelines and where, in these persons, the number needed to treat to prevent a coronary heart disease event is excessive [5] .
Diabetes Mellitus (DM)
As in the prior 2013 guidelines, the 2018 guidelines recommend at least a moderate-intensity statin for all persons aged 40-79 years with diabetes mellitus (DM) (class I recommendation), and now without the previously specified LDL-C range of 70-189 mg/dL for initiating a statin. There is continued emphasis on use of the risk calculator for identifying those at the highest risk indicated for more intensive statin therapy (class IIa recommendation). However, in considering a high-intensity statin, instead of being uniformly recommended for those with ≥ 7.5% risk, the new guidelines suggest this would be appropriate for those with DM who have two or more risk factors, with ezetimibe now a consideration (with high-intensity statin therapy) for those with a ≥ 20% 10-year ASCVD risk (class IIb recommendation). It should be noted, that while ezetimibe provided additional benefit beyond statin therapy among persons with DM in the IMPROVE-IT trial [6] , this was of course in addition to all enrollees having a recent (< 10 days) acute coronary syndrome (ACS) as the primary inclusion criterion.
Younger Persons with DM
New to the 2018 guidelines for DM management is consideration of statin therapy for those under age 40 years for those who have had type 1 DM for at least 20 years or type 2 DM for at least 10 years, CKD, albuminuria, retinopathy, neuropathy, or an ABI score < 0.9, although only with a class IIb recommendation. In fact, Rana and colleagues [7] recently showed DM for more than 10 years can be considered a coronary heart disease risk equivalent.
Coronary Calcium Screening in Diabetes
While CAC as a risk-enhancing factor is not mentioned here for persons with DM (although a CAC score of 0 is not recommended for de-risking a patient who has DM), CAC has been shown to be a robust risk stratifier in patients with DM, where it has been previously shown that those with CAC scores of ≥ 400 have ten times the risk of coronary heart disease events as those with scores of 0 [8] . Moreover, a CAC score of ≥ 100 indicates an ASCVD risk of at least 2% per year (e.g., 20% in 10 years) based on longer follow-up in a more recent paper [9] , where, like with those with a > 20% 10-year ASCVD risk as noted in the guidelines, high-intensity statin therapy with ezetimibe if needed could be potentially recommended. And for those with type 1 DM, the Epidemiology of Diabetes Interventions and Complications study recently showed that CAC significantly improves risk prediction for ASCVD events [10] .
Secondary Prevention

New "Very High Risk" Categorization
The most important change to the recommendations for treatment of persons with pre-existing ASCVD is the categorization of those at versus those not at "very high risk"
( Fig. 2 ). Those at very high risk are defined specifically as those with multiple major ASCVD events (recent ACS within the past 12 months, history of MI (other than recent ACS within 12 months), history of ischemic stroke, symptomatic peripheral arterial disease, or one of these major ASCVD events and multiple high-risk conditions, consisting of one of the following: age ≥ 65 years, heterozygous familial hypercholesterolemia, history of prior coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI), hypertension, CKD based on an estimated glomerular filtration rate of 15-59 mL/min/1.73 m 2 , current smoking, persistently elevated LDL-C ≥ 100 mg/dL despite maximally tolerated statin ± ezetimibe, or a history of congestive heart failure) ( Table 1 ). The intent here is to identify those at greatest absolute risk who would derive the greatest absolute risk reduction from the addition of non-statin therapies. Similarly, those with stable ASCVD for a year that have well-treated risk factors may accrue only modest additional benefit from these therapies. While in most cases such a categorization would identify those at highest risk, one could argue that certain situations may warrant greater clinical judgment to decide whether a patient is very high risk or not. For instance, the individual with a recent ACS who has heterozygous familial hypercholesterolemia only might be actually considered by some to be "very high risk" although they would by the current guideline be classified as "not at very high risk" due to not having multiple high-risk conditions in addition to the single major ASCVD event.
And conversely, someone with a prior MI, who had a PCI, stabilized for 5 years, and has mild hypertension would technically fall in the very high-risk group, but might actually be considered by some to be at lower risk than the example above. Again, the clinician needs to consider carefully the severity as well as timing (more recent would suggest higher risk) of both these major ASCVD events and highrisk conditions.
Use of Low-Density Lipoprotein Cholesterol Thresholds
Rather than the use of targets for initiation of therapy, the new guidelines note specific "thresholds" for LDL-C levels for when to initiate certain non-statin therapies. For instance, in those not at very high risk, ezetimibe (although only a class IIb recommendation) is given and only if high-intensity statin does not lower the LDL-C below 70 mg/dL. In those at very high risk, the initiation of ezetimibe is considered at an LDL-C threshold of 70 mg/dL on maximal statin therapy. A PCSK9 monoclonal antibody (mAb) is only considered (as a class IIa recommendation) after adding ezetimibe to maximal statin therapy if the LDL-C is still ≥ 70 mg/dL or non-high-density lipoprotein cholesterol is ≥ 100 mg/ dL. While the decision to consider ezetimibe more broadly than in the population studied in IMPROVE-IT (recent ACS within 10 days) may in part be due to its generic status, the opposite may be the case for the PCSK9 mAb therapies being recommended now to a more limited "very high-risk" ASCVD patient population, which is narrower than the more heterogenous ASCVD population studied in FOURIER and ODYSSEY trials, possibly because of the high cost of these products, which were not discounted substantially until the guidelines were already finalized.
Hypertriglyceridemia
Unlike the 2013 guidelines, the updated 2018 guidelines give specific guidance for persons with hypertriglyceridemia. While lifestyle management remains the emphasis for most persons with moderate hypertriglyceridemia, those with more elevated triglycerides (≥ 500 mg/dL) are considered as candidates for other measures such as statin therapy (among those aged 40-75 years with a 10-year ASCVD risk of ≥ 7.5%) (class IIa recommendation) as well as consumption of omega-3 fatty acids, a very low-fat diet, avoidance of refined carbohydrates and alcohol, and, if needed, fibrate therapy to prevent acute pancreatitis (class IIa recommendation). However, since the guidelines were written, the landmark results of the REDUCE-IT trial [11] demonstrated the value of icosapent ethyl in reducing ASCVD events by a remarkable 25% beyond statin therapy in persons with Table 1 Criteria for "very high risk" classification in persons with known ASCVD. Adapted from Grundy et al. [1] "Very high-risk" is defined as multiple major ASCVD events or one major ASCVD event and multiple high-risk conditions ABI ankle-brachial index, ACS acute coronary syndromes, ASCVD atherosclerotic cardiovascular disease, CABG coronary artery bypass graft surgery, CKD chronic kidney disease, eGFR estimated glomerular filtration rate, HF heart failure, LDL-C low-density lipoprotein cholesterol, MI myocardial infarction, PAD peripheral arterial disease, PCI percutaneous coronary intervention
Major ASCVD events
Recent ACS (within the past 12 months) History of MI (other than recent ACS event listed above) History of ischemic stroke Symptomatic PAD (history of claudication with ABI < 0.85, or previous revascularization or amputation) High-risk conditions Age ≥ 65 years Heterozygous familial hypercholesterolemia History of prior CABG or PCI outside of the major ASCVD event(s) Diabetes mellitus Hypertension CKD (eGFR 15-59 mL/min/1.73 m 2 ) Current smoking Persistently elevated LDL-C [LDL-C ≥ 100 mg/dL (≥ 2.6 mmol/L)] despite maximally tolerated statin therapy and ezetimibe History of congestive HF known ASCVD or diabetes and at least one risk factor who had triglycerides of 135-499 mg/dL. Further clinical trial evidence, such as results pending from the ongoing trials of other omega-3 fatty acid preparations and fibrates may influence future guideline releases regarding the use of nonstatin therapies. Of note, however, the American Diabetes Association have now updated their standards of medical care recommendations (2019) to include consideration of icosapent ethyl for persons with diabetes who have ASCVD or other risk factors, where despite a well-controlled LDL-C, triglycerides still remain at 130-499 mg/dL, with a class A recommendation [12] .
Other Special Populations
The 2018 guideline has notably gone further than its predecessor in addressing the appropriateness of statin therapy for other patient populations besides the original four statineligible groups. Additional specific guidance is now provided for older persons, children and adolescents, high-risk ethnic groups, women, persons with CKD, and persons with chronic inflammatory conditions, including HIV.
Older Persons
As in the prior guidelines, it is noted in persons aged 75 years and over that starting with a moderate-intensity statin is reasonable (class IIa recommendation). The updated 2018 guidelines, however, recommend stopping a statin in cases of functional decline, multimorbidity, frailty, or reduced life expectancy, because such conditions may limit the potential benefits of the statin (class IIa recommendation). And for the first time, in those aged 76-80 years, a CAC scan is noted to be reasonable to identify those with a zero calcium score for whom statin therapy may be withheld (class IIa recommendation).
Children and Adolescents
In children and adolescents, it is recommended that as early as age 2 years lipid screening can be used to identify familial hypercholesterolemia in those with a family history of early ASCVD or significant hypercholesterolemia, and consideration should be given to measuring lipids at least once between the ages of 9 and 11 in all others. Further, statin use is recommended in those aged at least 10 years with LDL-C ≥ 190 mg/dL or when LDL-C is ≥ 160 mg/dL and there is a clinical history consistent with familial hypercholesterolemia (class IIa recommendation).
High-Risk Ethnicities
For the first time, guidance is given to considering adjusting statin dosages according to race/ethnic features, which include differences in lipids and genetic polymorphisms in hepatic clearance pathways between Asian, South Asian, African-Americans, and Hispanics. In primary prevention, certain high risk ethnicities (e.g., South Asians) are considered risk enhancing factors. The importance of taking into account racial/ethnic preferences in heart-healthy diet counseling is also noted (class IIa recommendation).
Women
Of interest, the new guidelines give specific guidance to better inform treatment decisions in women, especially among those with early menopause or certain pregnancy-related conditions such as preeclampsia, all of which correlate with cardiovascular risk enhancers that favor statin treatment where there is uncertainty (class I recommendation). Additional guidance is also given to those who are sexually active or plan to become pregnant.
Chronic Kidney Disease and Dialysis
For the first time, the ACC/AHA guidelines provide guidance for persons with CKD not receiving dialysis. Among such patients with CKD aged 40-75 years with LDL-C levels of 70-189 mg/dL, treatment with a moderate-intensity statin alone or in combination with ezetimibe may be appropriate (class IIa recommendation). Among those with CKD and on dialysis, while it is not appropriate to start a statin, a statin can be continued among those already on a statin or if they also have ischemic heart disease.
Chronic Inflammatory Conditions and HIV
Finally, another addition to the current guidelines are recommendations for those with chronic inflammatory conditions and HIV. In such persons aged 40-75 years with LDL-C levels of 70-189 mg/dL, a moderate-or high-intensity statin is favored (class IIa recommendation). In addition, a fasting lipid profile should be performed before and after starting any anti-inflammatory or antiretroviral therapy.
Economic Value Considerations
The new guidelines also noted in patients with ASCVD the use of PCSK9 mAbs provides a "low cost value" based on mid-2018 list prices where costs exceeded US$150,000 per quality-adjusted life year (QALY) saved, with < US$50,000 per QALY considered to be a good cost value. For those with familial hypercholesterolemia without ASCVD, the cost value is uncertain. Since the publication of these guidelines, however, there have been dramatic cost reductions of approximately 60% for both of the PCSK9 mAb therapies, which, based on the costeffectiveness analysis done by the guideline authors, would amount to much lower costs per QALY, but not below the US$50,000 threshold, and further discounts would likely be needed. Such estimates of economic value, however, are highly dependent on the method of analysis, type of patients and duration of treatment. For example, the FOU-RIER trial has shown greater absolute benefit in certain types of patients, such as those with peripheral artery disease, multiple prior MIs, more recent MIs, and multiple high-risk features, as well as suggested greater benefits for those with longer duration of treatment, and likewise the ODYSSEY outcomes trial showed a greater benefit in those with baseline LDL-C ≥ 100 mg/dL [13] . It is likely that reserving these drugs for those at highest risk (e.g., the "very high-risk" subgroup of ASCVD patients) and only after the incremental addition of ezetimibe, as noted in the updated guidelines, is due to these cost considerations and the greater clinical efficacy (e.g., lowest number needed to treat) in those at highest risk.
Conclusions
The new multi-society cholesterol management guidelines provide further useful guidance for the appropriate application of well-grounded statin therapy in primary prevention as well as for which patients should be considered for non-statin therapies, particularly ezetimibe and PCSK9 mAbs given their proven efficacy for incremental ASCVD risk reduction in certain ASCVD populations. The guidelines are also landmark for providing recommendations for a broad range of special populations, particularly ethnic groups, women, children and adolescents, and those with CKD and chronic inflammatory conditions and HIV. Additional updates will likely consider not only the changing landscape with respect to new evidence-based therapies for reduction of ASCVD risk (e.g., icosapent ethyl and other emerging therapies), but also the changing costs of newer medications (e.g., PCSK9 mAb therapies) as well as emerging risk-enhancing measures that significantly impact treatment decisions.
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